Peptide · Fact sheet
BPC-157
Also known as Body Protection Compound 157
BPC-157 is often promoted for injury or gut healing, but it is not an FDA-approved medicine and reliable human clinical evidence is extremely limited.
What is BPC-157?
BPC-157 is a synthetic sequence described as being derived from a gastric protein fragment.
Claims about healing are largely extrapolated from animal and laboratory studies, which cannot show that the same benefits or risks apply to people.
Benefits & claims
Online discussions frequently mention tendon, ligament, muscle, bone, nerve, and gastrointestinal recovery.
The gap between confident marketing and sparse human evidence is the central fact readers should understand.
What the evidence supports
- Animal and laboratory studies have reported signals related to tissue repair and inflammation.
- Those findings are hypotheses for human research, not proven patient benefits.
Research areas
- Acute hamstring strain in a registered Phase 2 trial
- Tissue repair in animal models
- Gastrointestinal effects in animal models
- Inflammation and blood-vessel signaling in preclinical research
- Acute hamstring-strain repair in a registered trial
- Preclinical models of tissue injury and gastrointestinal conditions
Dosage & frequency
No established human regimenThere is no established human dosage or frequency for BPC-157 injury repair. A registered trial is a research plan, not proof of an effective treatment regimen.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- BPC-157 is an experimental peptide; oral, injected, and other formulations cannot be assumed equivalent.
Interactions & precautions
- Controlled human interaction data are insufficient for BPC-157; animal repair findings do not establish compatibility with medicines.
What is still unresolved
- Controlled human efficacy, route-specific exposure, repeated-use safety, and interaction data are still inadequate.
Side effects & risks
- Human short- and long-term safety are poorly characterized.
- FDA notes possible immune reactions, peptide-related impurities, and difficulty characterizing the active ingredient.
- Unapproved products may introduce contamination, incorrect-strength, sterility, or mislabeling risks.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchMost cited work is preclinical. There is no mature body of randomized human trials establishing safety and effectiveness for common promoted uses.
Studies
Registry record for an early human BPC-157 study, not evidence of established clinical benefit.
Peer-reviewed review focused largely on preclinical BPC-157 research.
Review discussing BPC-157 wound-healing research, primarily outside mature human efficacy trials.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
Nausea, fatigue, anxiety and fainting
A separate poster described nausea, marked tiredness, increased anxiety and passing out during exercise after starting a product labeled BPC-157.
Reported use in this account
- Product
- Product described as BPC-157
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Three days
The product and reported fainting episode were not independently verified. The amount unit in a reply cannot be resolved, so no usable amount is shown; the source does not establish an allergic mechanism.
Read the separate BPC-157 accountSleep: reported experiences
Severe anxiety, sleeplessness and chest tightness
A different person reported these symptoms after exposure to products labeled BPC-157 and TB-500, including seeking hospital assessment.
Reported use in this account
- Product
- Products described as BPC-157 and TB-500
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Subcutaneous injection
- Duration
- Three days before the severe episode
Other exposures described: TB-500
BPC-157 and TB-500 were used together, with neither contents nor causation independently verified. The stated amount cannot be allocated between the products; no BPC-specific amount or frequency can be resolved.
Read the adverse-experience reportMood: reported experiences
Severe anxiety, sleeplessness and chest tightness
A different person reported these symptoms after exposure to products labeled BPC-157 and TB-500, including seeking hospital assessment.
Reported use in this account
- Product
- Products described as BPC-157 and TB-500
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Subcutaneous injection
- Duration
- Three days before the severe episode
Other exposures described: TB-500
BPC-157 and TB-500 were used together, with neither contents nor causation independently verified. The stated amount cannot be allocated between the products; no BPC-specific amount or frequency can be resolved.
Read the adverse-experience reportNausea, fatigue, anxiety and fainting
A separate poster described nausea, marked tiredness, increased anxiety and passing out during exercise after starting a product labeled BPC-157.
Reported use in this account
- Product
- Product described as BPC-157
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Three days
The product and reported fainting episode were not independently verified. The amount unit in a reply cannot be resolved, so no usable amount is shown; the source does not establish an allergic mechanism.
Read the separate BPC-157 accountPain: reported experiences
Less knee pain during combined exposure
One person attributed a gradual reduction in longstanding knee pain to products labeled BPC-157 and TB-500 used together.
Reported use in this account
- Product
- Products described as BPC-157 and TB-500
- Amount
- 500 mcg of BPC-157 on the reported exposure days
- Frequency
- Five days a week
- Route
- Subcutaneous injection
- Duration
- Five weeks
Other exposures described: TB-500, reported at 500 mcg on the same exposure days
Two products were used, with no control group or independent assessment of healing. The account cannot separate their effects. TB-500 product labeling does not verify equivalence to full-length thymosin beta-4.
Read the knee-pain reportDigestion: reported experiences
Nausea, fatigue, anxiety and fainting
A separate poster described nausea, marked tiredness, increased anxiety and passing out during exercise after starting a product labeled BPC-157.
Reported use in this account
- Product
- Product described as BPC-157
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Three days
The product and reported fainting episode were not independently verified. The amount unit in a reply cannot be resolved, so no usable amount is shown; the source does not establish an allergic mechanism.
Read the separate BPC-157 accountHeart symptoms: reported experiences
Severe anxiety, sleeplessness and chest tightness
A different person reported these symptoms after exposure to products labeled BPC-157 and TB-500, including seeking hospital assessment.
Reported use in this account
- Product
- Products described as BPC-157 and TB-500
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Subcutaneous injection
- Duration
- Three days before the severe episode
Other exposures described: TB-500
BPC-157 and TB-500 were used together, with neither contents nor causation independently verified. The stated amount cannot be allocated between the products; no BPC-specific amount or frequency can be resolved.
Read the adverse-experience reportAcute illness: reported experiences
Nausea, fatigue, anxiety and fainting
A separate poster described nausea, marked tiredness, increased anxiety and passing out during exercise after starting a product labeled BPC-157.
Reported use in this account
- Product
- Product described as BPC-157
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Three days
The product and reported fainting episode were not independently verified. The amount unit in a reply cannot be resolved, so no usable amount is shown; the source does not establish an allergic mechanism.
Read the separate BPC-157 accountApproval status
BPC-157 is not FDA approved. A Phase 2 hamstring-strain trial is registered, and FDA lists BPC-157 among bulk substances for which compounded products may present significant safety risks and for which safety information is limited.
Early human clinical testing
A Phase 2 hamstring-strain trial is registered, but no BPC-157 product is FDA approved and the published evidence base remains mostly preclinical.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether animal findings translate to meaningful human benefits
- Long-term safety, cancer-related signaling concerns, interactions, and reproductive risks
- A reliable adverse-effect rate or risk profile
- Whether products sold under the name consistently contain the claimed substance
Summary
BPC-157 has preclinical tissue-repair findings, but controlled human evidence and safety data remain limited.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- clinical trialsClinicalTrials.gov: BPC-157 hamstring strain study
Registry record for an early human BPC-157 study, not evidence of established clinical benefit.
- pubmedBPC-157 preclinical gastrointestinal review
Peer-reviewed review focused largely on preclinical BPC-157 research.
- pubmedBPC-157 wound-healing review
Review discussing BPC-157 wound-healing research, primarily outside mature human efficacy trials.